salicylic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
analgesic anti-inflammatory	2416	69-72-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: choline salicylate choline subsalicylate salicylic acid 2-Carboxyphenol 2-Hydroxybenzenecarboxylic acid 2-Hydroxybenzoic acid imidazole salicylate sodium salicylate morpholine salicylate potassium salicylate	A compound obtained from the bark of the white willow and wintergreen leaves. It has bacteriostatic, fungicidal, and keratolytic actions. Molecular weight: 138.12 Formula: C7H6O3 CLOGP: 2.19 LIPINSKI: 0 HAC: 3 HDO: 2 TPSA: 57.53 ALOGS: -1.09 ROTB: 1

Molecule

Description

Molfile Inchi Smiles

Synonyms:

choline salicylate
choline subsalicylate
salicylic acid
2-Carboxyphenol
2-Hydroxybenzenecarboxylic acid
2-Hydroxybenzoic acid
imidazole salicylate
sodium salicylate
morpholine salicylate
potassium salicylate

A compound obtained from the bark of the white willow and wintergreen leaves. It has bacteriostatic, fungicidal, and keratolytic actions.

Molecular weight: 138.12
Formula: C7H6O3
CLOGP: 2.19
LIPINSKI: 0
HAC: 3
HDO: 2
TPSA: 57.53
ALOGS: -1.09
ROTB: 1

Drug dosage:

Dose	Unit	Route
3	g	O
3	g	O
7	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	2.51 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	15 %	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1898	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	704.54	16.45	216	7936	24160	63456710
Completed suicide	311.52	16.45	207	7945	145466	63335404
Chronic sinusitis	209.46	16.45	74	8078	12769	63468101
Paraesthesia oral	183.72	16.45	75	8077	19181	63461689
Procedural pain	175.50	16.45	75	8077	21494	63459376
Toxicity to various agents	126.68	16.45	157	7995	247093	63233777
Erythema	122.69	16.45	131	8021	175620	63305250
Therapeutic product effect incomplete	118.28	16.45	110	8042	124946	63355924
Vaginal flatulence	111.28	16.45	33	8119	3260	63477610
Skin burning sensation	105.93	16.45	45	8107	12689	63468181
Proctitis	94.98	16.45	33	8119	5408	63475462
Female genital tract fistula	87.95	16.45	34	8118	7525	63473345
Drug ineffective	81.50	16.45	305	7847	1044460	62436410
Radiculopathy	80.24	16.45	33	8119	8578	63472292
Vaginal discharge	78.14	16.45	33	8119	9165	63471705
Dyspepsia	78.02	16.45	80	8072	102116	63378754
Broncholithiasis	77.07	16.45	15	8137	238	63480632
Skin irritation	76.31	16.45	33	8119	9708	63471162
Lymph node calcification	73.01	16.45	15	8137	317	63480553
Skin exfoliation	65.71	16.45	50	8102	43052	63437818
Frequent bowel movements	62.07	16.45	38	8114	22984	63457886
Colitis ulcerative	60.16	16.45	39	8113	26052	63454818
Dry skin	57.49	16.45	52	8100	56835	63424035
Oral candidiasis	54.84	16.45	35	8117	22763	63458107
Bronchial wall thickening	50.54	16.45	15	8137	1484	63479386
Pain of skin	44.17	16.45	24	8128	11610	63469260
Drug hypersensitivity	42.80	16.45	111	8041	310576	63170294
Lower respiratory tract infection viral	38.99	16.45	11	8141	910	63479960
Lichen nitidus	37.56	16.45	7	8145	87	63480783
Exposure via ingestion	37.12	16.45	14	8138	2895	63477975
Colitis	37.00	16.45	38	8114	48490	63432380
Suspected suicide	34.92	16.45	17	8135	6551	63474319
Weight decreased	34.16	16.45	95	8057	276703	63204167
Rectal haemorrhage	33.12	16.45	36	8116	48994	63431876
Haematochezia	28.88	16.45	35	8117	53509	63427361
Chemical burn of skin	27.64	16.45	5	8147	52	63480818
Skin swelling	24.76	16.45	11	8141	3448	63477422
Infusion related reaction	24.32	16.45	78	8074	245443	63235427
Malaise	23.82	16.45	111	8041	415843	63065027
Obstructive airways disorder	23.04	16.45	20	8132	20679	63460191
Dysaesthesia	22.05	16.45	11	8141	4467	63476403
Sexual abuse	20.82	16.45	5	8147	219	63480651
Soft tissue necrosis	20.34	16.45	6	8146	581	63480289
Pyrexia	20.28	16.45	116	8036	470362	63010508
Nausea	19.64	16.45	181	7971	854290	62626580
Jarisch-Herxheimer reaction	18.24	16.45	5	8147	372	63480498
Drug intolerance	17.35	16.45	9	8143	308652	63172218
Systemic lupus erythematosus	17.29	16.45	3	8149	208915	63271955
Skin hyperpigmentation	16.53	16.45	10	8142	5911	63474959

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	290.02	17.90	172	4399	97996	34854364
Toxicity to various agents	85.20	17.90	117	4454	200245	34752115
Anal inflammation	75.57	17.90	20	4551	1280	34951080
SARS-CoV-2 test negative	65.58	17.90	17	4554	1003	34951357
Choroiditis	62.63	17.90	17	4554	1198	34951162
Skin burning sensation	54.07	17.90	21	4550	4622	34947738
Accident	52.37	17.90	21	4550	5026	34947334
Endophthalmitis	52.25	17.90	19	4552	3489	34948871
Proctalgia	46.50	17.90	20	4551	5703	34946657
Intraocular pressure increased	34.71	17.90	16	4555	5367	34946993
Dry skin	33.94	17.90	30	4541	31257	34921103
Erythema	31.89	17.90	48	4523	88732	34863628
Visual acuity reduced	31.71	17.90	22	4549	16127	34936233
Haemorrhoids	31.34	17.90	21	4550	14554	34937806
Body temperature increased	28.02	17.90	21	4550	17347	34935013
Eye pain	27.99	17.90	19	4552	13443	34938917
Chondritis	27.62	17.90	6	4565	164	34952196
Skin exfoliation	25.25	17.90	24	4547	27408	34924952
Appendicolith	25.00	17.90	15	4556	8586	34943774
Palmar-plantar erythrodysaesthesia syndrome	24.22	17.90	19	4552	16776	34935584
Suspected suicide	24.17	17.90	12	4559	4736	34947624
Exposure via ingestion	22.36	17.90	9	4562	2172	34950188
Appendicitis	21.89	17.90	17	4554	14790	34937570
Psoriasis	21.60	17.90	26	4545	38786	34913574
Condition aggravated	21.12	17.90	64	4507	192132	34760228
Post inflammatory pigmentation change	19.33	17.90	5	4566	292	34952068

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	559.43	14.90	380	11209	245387	79487412
Macular degeneration	202.09	14.90	72	11517	11224	79721575
Chronic sinusitis	192.08	14.90	72	11517	12954	79719845
Toxicity to various agents	190.65	14.90	268	11321	421272	79311527
Paraesthesia oral	160.60	14.90	72	11517	20399	79712400
Procedural pain	155.41	14.90	73	11516	23011	79709788
Skin burning sensation	144.89	14.90	59	11530	13213	79719586
Erythema	130.04	14.90	161	11428	223129	79509670
Vaginal flatulence	110.77	14.90	32	11557	2543	79730256
Therapeutic product effect incomplete	90.27	14.90	107	11482	141538	79591261
Female genital tract fistula	87.96	14.90	33	11556	5942	79726857
Skin irritation	86.44	14.90	39	11550	11201	79721598
Dry skin	83.04	14.90	73	11516	67922	79664877
Proctitis	82.04	14.90	32	11557	6400	79726399
Skin exfoliation	81.37	14.90	66	11523	55034	79677765
Vaginal discharge	77.43	14.90	32	11557	7431	79725368
Radiculopathy	75.50	14.90	33	11556	8791	79724008
Broncholithiasis	69.86	14.90	14	11575	228	79732571
Anal inflammation	67.02	14.90	19	11570	1411	79731388
Dyspepsia	64.14	14.90	79	11510	108608	79624191
Lymph node calcification	62.33	14.90	14	11575	401	79732398
Exposure via ingestion	56.45	14.90	23	11566	5151	79727648
SARS-CoV-2 test negative	54.38	14.90	16	11573	1355	79731444
Choroiditis	54.27	14.90	16	11573	1365	79731434
Suspected suicide	51.95	14.90	27	11562	10549	79722250
Frequent bowel movements	49.21	14.90	38	11551	29501	79703298
Pain of skin	46.37	14.90	28	11561	14585	79718214
Colitis ulcerative	45.83	14.90	39	11550	34703	79698096
Oral candidiasis	42.69	14.90	35	11554	29593	79703206
Bronchial wall thickening	36.75	14.90	14	11575	2627	79730172
Proctalgia	36.55	14.90	21	11568	9980	79722819
Lichen nitidus	36.47	14.90	7	11582	90	79732709
Accident	36.22	14.90	20	11569	8811	79723988
Endophthalmitis	36.20	14.90	18	11571	6410	79726389
Chemical burn of skin	34.64	14.90	7	11582	119	79732680
Palmar-plantar erythrodysaesthesia syndrome	31.57	14.90	31	11558	33103	79699696
Lower respiratory tract infection viral	30.51	14.90	10	11579	1210	79731589
Malaise	29.58	14.90	145	11444	489724	79243075
Drug hypersensitivity	29.52	14.90	103	11486	298813	79433986
Soft tissue necrosis	29.07	14.90	9	11580	906	79731893
Psoriasis	27.70	14.90	48	11541	89539	79643260
Weight decreased	27.32	14.90	113	11476	355085	79377714
Rectal haemorrhage	25.06	14.90	42	11547	76258	79656541
Skin swelling	24.88	14.90	12	11577	4002	79728797
Appendicolith	23.61	14.90	15	11574	8536	79724263
Intraocular pressure increased	22.60	14.90	15	11574	9190	79723609
Pyrexia	21.95	14.90	171	11418	678538	79054261
Chondritis	21.73	14.90	5	11584	160	79732639
Infusion related reaction	21.56	14.90	78	11511	230159	79502640
Colitis	21.01	14.90	38	11551	73269	79659530
Scab	18.48	14.90	14	11575	10558	79722241
Visual acuity reduced	18.30	14.90	22	11567	29447	79703352
Appendicitis	17.15	14.90	18	11571	20776	79712023
Dermatitis	16.78	14.90	18	11571	21303	79711496
Post inflammatory pigmentation change	16.52	14.90	5	11584	467	79732332
Sensitive skin	16.32	14.90	7	11582	1780	79731019
Haematochezia	16.30	14.90	38	11551	87607	79645192
Poisoning	15.91	14.90	19	11570	25253	79707546
Skin atrophy	15.71	14.90	10	11579	5708	79727091
Eye pain	15.55	14.90	23	11566	37555	79695244
Dysaesthesia	15.51	14.90	10	11579	5838	79726961
Haemorrhoids	15.30	14.90	20	11569	29108	79703691
Anal erosion	14.90	14.90	3	11586	50	79732749

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D01AE12	DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Other antifungals for topical use
ATC	N02BA03	NERVOUS SYSTEM ANALGESICS OTHER ANALGESICS AND ANTIPYRETICS Salicylic acid and derivatives
ATC	N02BA04	NERVOUS SYSTEM ANALGESICS OTHER ANALGESICS AND ANTIPYRETICS Salicylic acid and derivatives
ATC	N02BA08	NERVOUS SYSTEM ANALGESICS OTHER ANALGESICS AND ANTIPYRETICS Salicylic acid and derivatives
ATC	N02BA12	NERVOUS SYSTEM ANALGESICS OTHER ANALGESICS AND ANTIPYRETICS Salicylic acid and derivatives
ATC	N02BA16	NERVOUS SYSTEM ANALGESICS OTHER ANALGESICS AND ANTIPYRETICS Salicylic acid and derivatives
ATC	S01BC08	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFLAMMATORY AGENTS Antiinflammatory agents, non-steroids
MeSH PA	D000700	Analgesics
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D000894	Anti-Inflammatory Agents, Non-Steroidal
MeSH PA	D018501	Antirheumatic Agents
MeSH PA	D016861	Cyclooxygenase Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
CHEBI has role	CHEBI:35441	antiinfective agents
CHEBI has role	CHEBI:35718	antifungal agents
CHEBI has role	CHEBI:37848	plant hormones
CHEBI has role	CHEBI:50176	keratolytic drugs
CHEBI has role	CHEBI:73181	ascorbate peroxidase inhibitor
CHEBI has role	CHEBI:76924	plant metabolites
CHEBI has role	CHEBI:84735	algal metabolites
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000935	Antifungal Agents
MeSH PA	D003879	Dermatologic Agents
MeSH PA	D007641	Keratolytic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Tinea pedis	indication	6020002	DOID:12403
Pain	indication	22253000
Greasy skin	indication	42273000
Seborrheic dermatitis	indication	50563003	DOID:8741
Allergic rhinitis	indication	61582004
Verruca plantaris	indication	63440008	DOID:13775
Rheumatoid arthritis	indication	69896004	DOID:7148
Common cold	indication	82272006	DOID:10459
Tinea corporis	indication	84849002
Acne vulgaris	indication	88616000
Pityriasis simplex	indication	200767005
Disorder of keratinization	indication	277905003
Fever	indication	386661006
Hyperkeratosis	indication	396228006
Osteoarthritis	indication	396275006
Synovitis	indication	416209007	DOID:2703
Calluses and Corns	indication
Crohn's disease	off-label use	34000006
Tendinitis	off-label use	34840004	DOID:971
Rheumatic fever	off-label use	58718002	DOID:1586
Ulcerative colitis	off-label use	64766004	DOID:8577
Tenosynovitis	off-label use	67801009	DOID:970
Juvenile rheumatoid arthritis	off-label use	410795001
Itching of skin	off-label use	418363000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.81	acidic
pKa2	12.79	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN	Ki	5.15	CHEMBL
Carbonic anhydrase 1	Enzyme	P00915	CAH1_HUMAN	Ki	5	CHEMBL
Carbonic anhydrase 4	Enzyme	P22748	CAH4_HUMAN	Ki	4.95	CHEMBL
Carbonic anhydrase 9	Enzyme	Q16790	CAH9_HUMAN	Ki	4.10	CHEMBL
Carbonic anhydrase 12	Enzyme	O43570	CAH12_HUMAN	Ki	5.06	CHEMBL
Carbonic anhydrase 7	Enzyme	P43166	CAH7_HUMAN	Ki	4.09	CHEMBL
Carbonic anhydrase 6	Enzyme	P23280	CAH6_HUMAN	Ki	4.92	CHEMBL
Carbonic anhydrase 14	Enzyme	Q9ULX7	CAH14_HUMAN	Ki	4.30	CHEMBL
High mobility group protein B1	Nuclear other	P09429	HMGB1_HUMAN	Kd	6	CHEMBL
Nicotinate phosphoribosyltransferase	Enzyme	Q6XQN6	PNCB_HUMAN	Ki	9.80	CHEMBL
Salicylic acid-binding protein 2	Enzyme		SABP2_TOBAC			WOMBAT-PK
Carbonic anhydrase 13	Enzyme		CAH13_MOUSE	Ki	4.17	CHEMBL
Polyphenol oxidase 2	Enzyme		PPO2_AGABI	IC50	4	CHEMBL
Carbonic anhydrase 15	Enzyme		CAH15_MOUSE	Ki	5.14	CHEMBL
Solute carrier family 22 member 20	Transporter		S22AK_MOUSE	Ki	4.36	CHEMBL

External reference:

ID	Source
4018663	VUID
N0000146974	NUI
D00097	KEGG_DRUG
2016-36-6	SECONDARY_CAS_RN
36364-49-5	SECONDARY_CAS_RN
54-21-7	SECONDARY_CAS_RN
147-90-0	SECONDARY_CAS_RN
578-36-9	SECONDARY_CAS_RN
4018419	VANDF
4018434	VANDF
4018663	VANDF
4018996	VANDF
C0036079	UMLSCUI
CHEBI:16914	CHEBI
SAL	PDB_CHEM_ID
CHEMBL424	ChEMBL_ID
DB00936	DRUGBANK_ID
CHEMBL2104095	ChEMBL_ID
CHEMBL2104788	ChEMBL_ID
CHEMBL447868	ChEMBL_ID
D020156	MESH_DESCRIPTOR_UI
338	PUBCHEM_CID
C015075	MESH_SUPPLEMENTAL_RECORD_UI
4306	IUPHAR_LIGAND_ID
O414PZ4LPZ	UNII
DB14006	DRUGBANK_ID
DB13860	DRUGBANK_ID
20974	RXNORM
4438	MMSL
5235	MMSL
5439	MMSL
5494	MMSL
9170	MMSL
d00492	MMSL
d00843	MMSL
001586	NDDF
001590	NDDF
001592	NDDF
001951	NDDF
005692	NDDF
006027	NDDF
370179008	SNOMEDCT_US
387253001	SNOMEDCT_US
387411000	SNOMEDCT_US
46741005	SNOMEDCT_US
65302009	SNOMEDCT_US
72968006	SNOMEDCT_US
D012980	MESH_DESCRIPTOR_UI
CHEMBL3707214	ChEMBL_ID
CHEMBL3707342	ChEMBL_ID
1938	INN_ID
5485	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
SKIN MEDICA Purifying Foaming Wash	HUMAN OTC DRUG LABEL	1	0023-4948	LIQUID	20 mg	TOPICAL	OTC monograph final	10 sections
SKIN MEDICA Purifying Foaming Wash	HUMAN OTC DRUG LABEL	1	0023-4948	LIQUID	20 mg	TOPICAL	OTC monograph final	10 sections
DHS SAL4 oz.	HUMAN OTC DRUG LABEL	1	0096-0738	SHAMPOO	0.04 g	TOPICAL	OTC monograph final	8 sections
Zapzyt Acne Wash Cleanser	HUMAN OTC DRUG LABEL	1	0295-0071	GEL	2 g	TOPICAL	OTC monograph final	9 sections
Zapzyt Acne Wash Cleanser	HUMAN OTC DRUG LABEL	1	0295-9055	GEL	2 g	TOPICAL	OTC monograph final	10 sections
Cetaphil Gentle Clear Mattifying Acne Moisturizer	HUMAN OTC DRUG LABEL	1	0299-4117	LOTION	5 mg	TOPICAL	OTC monograph final	9 sections
Cetaphil Gentle Clear Mattifying Acne Moisturizer	HUMAN OTC DRUG LABEL	1	0299-4117	LOTION	5 mg	TOPICAL	OTC monograph final	9 sections
Cetaphil Gentle Clear Clarifying Acne Cleanser	HUMAN OTC DRUG LABEL	1	0299-4119	CREAM	20 mg	TOPICAL	OTC monograph final	10 sections
Cetaphil Gentle Clear Clarifying Acne Cleanser	HUMAN OTC DRUG LABEL	1	0299-4119	CREAM	20 mg	TOPICAL	OTC monograph final	10 sections
Cetaphil Acne Relief Body Wash	HUMAN OTC DRUG LABEL	1	0299-4121	GEL	20 mg	TOPICAL	OTC monograph final	10 sections
Cetaphil Acne Relief Body Wash	HUMAN OTC DRUG LABEL	1	0299-4121	GEL	20 mg	TOPICAL	OTC monograph final	10 sections
Differin Acne Clearing Body Wash	HUMAN OTC DRUG LABEL	1	0299-4131	GEL	20 mg	TOPICAL	OTC monograph final	11 sections
Differin Acne Clearing Body	HUMAN OTC DRUG LABEL	1	0299-4132	AEROSOL, SPRAY	2 g	TOPICAL	OTC monograph final	11 sections
Cetaphil Gentle Clear Triple-Action Acne Serum	HUMAN OTC DRUG LABEL	1	0299-4135	SOLUTION	5 mg	TOPICAL	OTC monograph final	9 sections
Differin Acne Clearing Body Scrub	HUMAN OTC DRUG LABEL	1	0299-4609	LIQUID	20 mg	TOPICAL	OTC monograph final	10 sections
Differin Acne Clearing Body Scrub	HUMAN OTC DRUG LABEL	1	0299-4609	LIQUID	20 mg	TOPICAL	OTC monograph final	10 sections
Almay Clear Complexion Liquid Makeup for Oily Skin	HUMAN OTC DRUG LABEL	1	0311-0715	LIQUID	0.50 mg	TOPICAL	OTC monograph final	7 sections
Almay Clear Complexion Blemish Healing Spot Concealer	HUMAN OTC DRUG LABEL	1	0311-0716	LIQUID	2 mg	TOPICAL	OTC monograph final	8 sections
Almay Clear Complexion Blemish Healing Spot Concealer	HUMAN OTC DRUG LABEL	1	0311-0718	LIQUID	0.01 g	TOPICAL	OTC monograph final	8 sections
Almay Clear Complexion Liquid Makeup	HUMAN OTC DRUG LABEL	1	0311-0720	LIQUID	2 mg	TOPICAL	OTC monograph final	8 sections
Almay Clear Complexion Pressed Powder	HUMAN OTC DRUG LABEL	1	0311-0721	POWDER	0.00 g	TOPICAL	OTC monograph final	8 sections
Almay Clear Complexion Blemish Armor	HUMAN OTC DRUG LABEL	1	0311-0722	LIQUID	2 mg	TOPICAL	OTC monograph final	10 sections
ALMAY CLEAR COMPLEXION MAKEUP	HUMAN OTC DRUG LABEL	1	0311-0724	EMULSION	1 mg	TOPICAL	OTC monograph final	7 sections
ALMAY CLEAR COMPLEXION CONCEALER	HUMAN OTC DRUG LABEL	1	0311-0725	LIQUID	2 mg	TOPICAL	OTC monograph final	8 sections
PanOxyl Clarifying Exfoliant	HUMAN OTC DRUG LABEL	1	0316-0296	LIQUID	2 g	TOPICAL	OTC monograph final	12 sections
Salicylic acid	HUMAN OTC DRUG LABEL	1	0363-0017	CREAM	5.05 mg	TOPICAL	OTC monograph final	10 sections
Salicylic acid	HUMAN OTC DRUG LABEL	1	0363-0017	CREAM	5.05 mg	TOPICAL	OTC monograph final	10 sections
Charcoal Blackhead Clearing Scrub	HUMAN OTC DRUG LABEL	1	0363-0027	CREAM	20.60 mg	TOPICAL	OTC monograph final	11 sections
Charcoal Blackhead Clearing Scrub	HUMAN OTC DRUG LABEL	1	0363-0027	CREAM	20.60 mg	TOPICAL	OTC monograph final	11 sections
Salicylic Acid	HUMAN OTC DRUG LABEL	1	0363-0203	PATCH	40 mg	TOPICAL	OTC monograph final	12 sections